Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Completed 5Withdrawn 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Thoracic 6

Conditions

Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 5Carcinoma, Hepatocellular 4Neoplasms 2Lung Neoplasms 2Liver Neoplasms 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Liver Diseases 1Hepatitis 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrosis 1Carcinoma, Squamous Cell 1Breast Neoplasms, Male 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × bavituximab × Clear all
NCT01323062 2018-12-04

Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

UNC Lineberger Comprehensive Cancer Center

Phase 1 Completed
26 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01999673 2017-04-21

SUNRISE

Peregrine Pharmaceuticals

Phase 3 Completed
582 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01138163 2017-04-19

Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer

Peregrine Pharmaceuticals

Phase 2 Completed
121 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01160601 2017-04-19

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

Peregrine Pharmaceuticals

Phase 2 Completed
86 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02673814 2016-08-01

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Peregrine Pharmaceuticals

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00687817 2011-03-24

Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer

Peregrine Pharmaceuticals

Phase 2 Completed
49 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡